Sheraz Butt1, Jørgen L Jeppesen1, Line Vinderslev Iversen2,3, Mogens Fenger4, Jesper Eugen-Olsen5, Charlotte Andersson6, Søren Jacobsen7. 1. Department of Internal Medicine, Amager and Hvidovre University Hospital, Glostrup, Denmark. 2. Department of Dermatology, Bispebjerg University Hospital, Copenhagen, Denmark. 3. Department of Dermatology and Allergy, Odense University Hospital, Odense, Denmark. 4. Department of Clinical Biochemistry, Amager and Hvidovre University Hospital, Hvidovre, Denmark. 5. Clinical Research Centre, Amager and Hvidovre University Hospital, Hvidovre, Denmark. 6. Department of Cardiology, Herlev-Gentofte University Hospital, Hellerup, Denmark. 7. Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Disease, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Abstract
OBJECTIVE: We assessed the association of suPAR (soluble urokinase plasminogen activator receptor) plasma levels with fibrotic and vascular manifestations in patients with systemic sclerosis (SSc). METHODS: suPAR plasma levels were measured in 121 consecutive patients with SSc and correlated to pulmonary and vascular features of SSc, including interstitial lung disease as characterized by percentage of predicted CO diffusing capacity (DLco) and forced vital capacity (FVC), pulmonary fibrosis by computed tomography, and pulmonary arterial hypertension, telangiectasias, and digital ulcers. RESULTS: Overall, 121 SSc patients (84% females; mean age, 57 ± 12 [range: 22-79] years) were enrolled; 35% had diffuse cutaneous SSc. suPAR plasma levels ranged from 1.3-10.2 [median: 2.9 (p25-p75: 2.3-3.9)] ng/mL. Log(suPAR) levels correlated with DLco (r = -0.41, p <0.0001) and FVC (r = -0.26, p = 0.004), also when adjusted for age, sex, and pulmonary hypertension. A suPAR cut-off level of >2.5 ng/mL showed a sensitivity of 91% for identifying patients with either DLco <50% or FVC < 60% of the predicted values. Similarly, 19 (90%) had a suPAR >2.5 ng/mL among those diagnosed with pulmonary fibrosis vs. 59 (60%) among those who did not (p = 0.008). suPAR values were not associated with vascular manifestations. CONCLUSION: suPAR levels strongly correlated with pulmonary involvement in SSc. Future studies should test if suPAR estimation can be used for surveillance of severe pulmonary involvement in SSc.
OBJECTIVE: We assessed the association of suPAR (soluble urokinase plasminogen activator receptor) plasma levels with fibrotic and vascular manifestations in patients with systemic sclerosis (SSc). METHODS:suPAR plasma levels were measured in 121 consecutive patients with SSc and correlated to pulmonary and vascular features of SSc, including interstitial lung disease as characterized by percentage of predicted CO diffusing capacity (DLco) and forced vital capacity (FVC), pulmonary fibrosis by computed tomography, and pulmonary arterial hypertension, telangiectasias, and digital ulcers. RESULTS: Overall, 121 SSc patients (84% females; mean age, 57 ± 12 [range: 22-79] years) were enrolled; 35% had diffuse cutaneous SSc. suPAR plasma levels ranged from 1.3-10.2 [median: 2.9 (p25-p75: 2.3-3.9)] ng/mL. Log(suPAR) levels correlated with DLco (r = -0.41, p <0.0001) and FVC (r = -0.26, p = 0.004), also when adjusted for age, sex, and pulmonary hypertension. A suPAR cut-off level of >2.5 ng/mL showed a sensitivity of 91% for identifying patients with either DLco <50% or FVC < 60% of the predicted values. Similarly, 19 (90%) had a suPAR >2.5 ng/mL among those diagnosed with pulmonary fibrosis vs. 59 (60%) among those who did not (p = 0.008). suPAR values were not associated with vascular manifestations. CONCLUSION:suPAR levels strongly correlated with pulmonary involvement in SSc. Future studies should test if suPAR estimation can be used for surveillance of severe pulmonary involvement in SSc.
Authors: L V Iversen; O Østergaard; S Ullman; C T Nielsen; P Halberg; T Karlsmark; N H H Heegaard; S Jacobsen Journal: Scand J Rheumatol Date: 2013-09-09 Impact factor: 3.641
Authors: J Eugen-Olsen; O Andersen; A Linneberg; S Ladelund; T W Hansen; A Langkilde; J Petersen; T Pielak; L N Møller; J Jeppesen; S Lyngbaek; M Fenger; M H Olsen; P R Hildebrandt; K Borch-Johnsen; T Jørgensen; S B Haugaard Journal: J Intern Med Date: 2010-05-28 Impact factor: 8.989
Authors: Gergely Toldi; Gabriella Bekő; Gabriella Kádár; Emília Mácsai; László Kovács; Barna Vásárhelyi; Attila Balog Journal: Clin Chem Lab Med Date: 2013-02 Impact factor: 3.694
Authors: Xiaochun Liu; Maureen D Mayes; Claudia Pedroza; Hilda T Draeger; Emilio B Gonzalez; Brock E Harper; John D Reveille; Shervin Assassi Journal: Arthritis Care Res (Hoboken) Date: 2013-08 Impact factor: 4.794
Authors: Anna Lis-Święty; Małgorzata Widuchowska; Ligia Brzezińska-Wcisło; Eugeniusz Kucharz Journal: J Int Med Res Date: 2018-03-07 Impact factor: 1.671
Authors: Sheraz A Butt; Jørgen L Jeppesen; Christine Fuchs; Mette Mogensen; Merete Engelhart; Christian Torp-Pedersen; Gunnar H Gislason; Søren Jacobsen; Charlotte Andersson Journal: BMC Rheumatol Date: 2018-12-07
Authors: Willis S Bowman; Chad A Newton; Angela L Linderholm; Megan L Neely; Janelle Vu Pugashetti; Bhavika Kaul; Vivian Vo; Gabrielle A Echt; William Leon; Rupal J Shah; Yong Huang; Christine Kim Garcia; Paul J Wolters; Justin M Oldham Journal: Lancet Respir Med Date: 2022-01-18 Impact factor: 102.642